export interface BlogPost {
  slug: string;
  title: string;
  metaDescription: string;
  publishedAt: string;
  category: string;
  productId: string | null;
  sections: { heading?: string; body: string }[];
}

export const posts: BlogPost[] = [
  {
    slug: "what-is-bpc-157",
    title: "What is BPC-157? A Researcher's Guide",
    metaDescription:
      "An in-depth research overview of BPC-157, a synthetic 15-amino acid peptide derived from human gastric protein. Mechanisms, study models, and sourcing guidance.",
    publishedAt: "2025-01-15",
    category: "Recovery & Healing",
    productId: "bpc-157",
    sections: [
      {
        body: "BPC-157 — Body Protection Compound 157 — is a synthetic pentadecapeptide comprising 15 amino acids derived from a partial sequence of human gastric juice protein BPC. First isolated in the 1990s, it has since become one of the most studied peptide compounds in preclinical tissue-repair and gastrointestinal research. This guide covers what the compound is, how it has been studied, and what researchers should know before working with it.",
      },
      {
        heading: "Molecular Identity and Stability",
        body: "BPC-157 has the amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with a molecular weight of approximately 1419.5 Da. Unlike many peptides, BPC-157 demonstrates notable stability across a range of pH environments and has been used in both aqueous and acidic model systems without significant degradation. It is typically supplied as a lyophilized powder for reconstitution with bacteriostatic water prior to use in in vitro or preclinical protocols.",
      },
      {
        heading: "Research Applications and Study Models",
        body: "The preponderance of BPC-157 research has been conducted in rodent models examining tissue repair, mucosal healing, and inflammatory signaling. Studies published in peer-reviewed journals have investigated its effects on gastrointestinal integrity — specifically mucosal ulcer models, inflammatory bowel models, and anastomotic healing. Separately, a body of preclinical work has explored its activity in musculoskeletal models involving tendon and ligament tissue, where researchers have observed upregulation of growth factor receptor expression and angiogenic signaling markers.",
      },
      {
        heading: "Mechanisms Under Investigation",
        body: "BPC-157's proposed mechanisms center on modulation of the nitric oxide (NO) system, interaction with growth hormone receptor pathways, and upregulation of vascular endothelial growth factor (VEGF). In gastrointestinal research specifically, it appears to influence FAK-paxillin and EGR-1 expression. Researchers have also studied its interaction with the dopaminergic and serotonergic systems in CNS models, though this line of inquiry remains early-stage. It is critical to note that all of these mechanisms have been characterized in in vitro cell cultures or animal models — no clinical data exists.",
      },
      {
        heading: "Important Research Considerations",
        body: "BPC-157 has not been approved by the FDA or any regulatory agency for use in humans. All published mechanistic data originates from controlled preclinical settings. Researchers designing protocols with BPC-157 should reference the primary literature directly and treat all published findings as model-specific. Purity and batch consistency are critical variables — researchers should request a Certificate of Analysis confirming HPLC purity and mass spectrometry identity verification before use.",
      },
      {
        body: "PeptoBuy supplies research-grade BPC-157 as a lyophilized powder (10 mg per vial) for qualified researchers and laboratories. Each batch is independently third-party tested with COA available on request. For in vitro research use only — not for human or animal consumption.",
      },
    ],
  },

  {
    slug: "what-is-tb-500",
    title: "TB-500 Peptide: Research Overview",
    metaDescription:
      "A research-focused overview of TB-500, a synthetic analogue of Thymosin Beta-4. Covers structure, preclinical study data, mechanisms, and laboratory sourcing.",
    publishedAt: "2025-01-22",
    category: "Recovery & Healing",
    productId: "tb-500",
    sections: [
      {
        body: "TB-500 is the synthetic analogue of Thymosin Beta-4 (Tβ4), a 43-amino acid protein originally isolated from bovine thymus tissue. The specific fragment used in research — typically the central actin-binding domain sequence Ac-LKKTETQ — exhibits high affinity for G-actin monomers and has been studied extensively in models of tissue repair, wound healing, and inflammation modulation. This overview summarizes current research findings and key considerations for laboratory use.",
      },
      {
        heading: "Structure and Actin-Binding Properties",
        body: "Thymosin Beta-4 belongs to the beta-thymosin family of small acidic peptides that regulate actin polymerization. The peptide's core tetrapeptide motif LKKTET binds monomeric actin (G-actin), preventing its incorporation into filamentous actin (F-actin). This regulation of actin dynamics is central to cytoskeletal remodeling processes, which underlie cell migration — a critical early step in wound closure and tissue regeneration models. TB-500 has a molecular weight of approximately 4963 Da when synthesized as the full Tβ4 sequence.",
      },
      {
        heading: "Preclinical Study Models",
        body: "TB-500 has been studied in multiple preclinical contexts. In dermal wound models, researchers have documented accelerated re-epithelialization and increased laminin-5 and collagen IV expression at wound margins. Cardiac ischemia models have explored whether Tβ4 promotes cardiomyocyte survival and vessel remodeling following experimental MI. Separately, ocular surface research has examined its role in corneal repair and dry-eye models, with some studies noting modulation of MMP-2 activity. In neurological model work, Tβ4 has been studied in the context of oligodendrocyte differentiation and remyelination signaling.",
      },
      {
        heading: "Anti-Inflammatory Signaling",
        body: "Beyond direct actin regulation, TB-500 research has identified downstream effects on inflammatory mediator expression. Studies in macrophage culture models report downregulation of NF-κB-dependent cytokine output (IL-1β, TNF-α) following Tβ4 treatment. The peptide has also been linked to upregulation of anti-inflammatory mediators including IL-10 in specific tissue contexts. Researchers should be aware that these effects are model-specific and dose-dependent — extrapolation across tissue types requires independent verification.",
      },
      {
        heading: "Research Purity and Protocol Notes",
        body: "Batch purity is a particularly sensitive variable for TB-500 research. Sequence truncations or acetylation errors during synthesis can alter binding affinity meaningfully. Researchers should confirm HPLC purity of ≥98% and request MS identity confirmation (expected m/z matching the theoretical mass of the synthesized fragment) before incorporating any lot into a protocol. Lyophilized TB-500 should be stored at −20°C and reconstituted with bacteriostatic water at the time of use.",
      },
      {
        body: "PeptoBuy supplies research-grade TB-500 (10 mg lyophilized, ≥98% purity) for qualified laboratories. COA with HPLC and MS data is available on request for every batch. For in vitro research use only — not for human or animal consumption.",
      },
    ],
  },

  {
    slug: "what-is-rtglp3",
    title: "RTGLP3: GLP Receptor Research Compound Guide",
    metaDescription:
      "Research overview of RTGLP3, a triple GLP receptor agonist peptide. Covers receptor pharmacology, metabolic research models, and laboratory sourcing.",
    publishedAt: "2025-02-05",
    category: "Weight Loss",
    productId: "rtglp3",
    sections: [
      {
        body: "RTGLP3 is a novel triple GLP receptor agonist compound designed for advanced metabolic research. As the class of GLP-1 receptor agonists has expanded into dual and now triple agonists targeting GLP-1R, GLP-2R, and related receptors simultaneously, RTGLP3 represents the leading edge of that pharmacological progression. This guide provides a research-oriented overview of the compound, its receptor targets, and the current state of the associated scientific literature.",
      },
      {
        heading: "GLP Receptor Pharmacology Background",
        body: "Glucagon-like peptide receptors belong to the class B1 subfamily of G protein-coupled receptors (GPCRs). GLP-1R is expressed in pancreatic beta cells, the hypothalamus, and peripheral tissues, and its activation promotes glucose-dependent insulin secretion, gastric emptying delay, and appetite-regulating signaling through CNS pathways. GLP-2R is expressed predominantly in intestinal epithelial cells and enteric neurons, where it modulates mucosal growth, barrier integrity, and nutrient absorption. Triple agonists designed to engage both receptor subtypes — along with additional targets — are under investigation for their potential additive or synergistic effects on metabolic regulation.",
      },
      {
        heading: "Metabolic Research Models",
        body: "Research interest in triple GLP receptor agonists has been driven by preclinical results suggesting that simultaneous engagement of multiple GLP receptor subtypes may produce more pronounced effects on body weight, energy expenditure, and glycemic control than single-target approaches. Rodent diet-induced obesity (DIO) models have been the primary tool for characterizing these effects. Endpoints in published DIO studies have included body weight trajectory, food intake reduction, adipose tissue volume change, fasting glucose normalization, and insulin sensitivity markers. RTGLP3 follows the structural and pharmacological rationale established by this body of work.",
      },
      {
        heading: "Research Considerations",
        body: "Triple GLP receptor agonists are among the most complex peptide compounds available for research use. Their in vitro binding profiles — receptor affinity, selectivity ratios, cAMP potency assays — require careful characterization before in vivo models are designed. Researchers should be aware that receptor expression varies across species, and translation of preclinical findings from murine to human biology is not straightforward. All RTGLP3 research should be conducted under institutional protocols appropriate for the model organisms involved.",
      },
      {
        heading: "Compound Integrity and Stability",
        body: "GLP receptor agonist peptides are structurally complex and prone to aggregation, deamidation, and oxidation under improper storage conditions. Lyophilized stock should be stored at −20°C and protected from humidity. Reconstituted solutions should be used promptly and not subjected to repeated freeze-thaw cycles. HPLC purity confirmation and mass spectrometry identity verification are essential QC steps before any lot enters a research protocol.",
      },
      {
        body: "PeptoBuy supplies RTGLP3 in 10 mg, 20 mg, and 30 mg lyophilized vials for qualified researchers and institutions. Each batch undergoes independent third-party analysis with COA available on request. For in vitro and preclinical research use only — not for human or animal consumption.",
      },
    ],
  },

  {
    slug: "what-is-mots-c",
    title: "MOTS-C: Mitochondrial Peptide Research",
    metaDescription:
      "Research guide for MOTS-C, a mitochondria-derived peptide that activates AMPK signaling pathways. Covers metabolic research models, mechanisms, and sourcing.",
    publishedAt: "2025-02-18",
    category: "Recovery & Healing",
    productId: "mots-c",
    sections: [
      {
        body: "MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA type-C) is a 16-amino acid peptide encoded within the mitochondrial genome — specifically within the 12S rRNA gene. Discovered in 2015 by a team led by Changhan David Lee at the University of Southern California, MOTS-C represents a new class of mitochondria-derived peptides (MDPs) with systemic signaling functions. Its discovery challenged the classical view of mitochondria as purely metabolic organelles and opened a new line of research into mitochondrial-nuclear communication.",
      },
      {
        heading: "AMPK Pathway Activation",
        body: "MOTS-C's primary characterized mechanism involves activation of AMPK (AMP-activated protein kinase), the central cellular energy sensor. In the proposed model, MOTS-C translocates from mitochondria to the nucleus under conditions of metabolic stress, where it interacts with AMPK-related signaling cascades to regulate gene expression associated with energy homeostasis. AMPK activation has broad downstream effects: suppression of anabolic pathways (mTORC1 signaling, lipogenesis, gluconeogenesis) and promotion of catabolic processes (fatty acid oxidation, autophagy, glucose uptake via GLUT4 translocation).",
      },
      {
        heading: "Insulin Sensitivity and Metabolic Research",
        body: "Initial studies characterizing MOTS-C focused on its effects in insulin resistance models. In murine high-fat diet models, MOTS-C administration was associated with improvements in insulin-stimulated glucose uptake, reduction in fasting glucose, and modulation of adipose tissue inflammation markers. Subsequent work has examined its role in skeletal muscle metabolism, where AMPK-dependent GLUT4 upregulation is a key research endpoint. Aging models have also been of interest, as MOTS-C plasma levels appear to decline with age in both rodent and human observational studies.",
      },
      {
        heading: "Mitochondrial-Nuclear Communication",
        body: "The broader significance of MOTS-C research extends beyond its acute metabolic effects. As a retrograde mitochondria-to-nucleus signaling peptide, MOTS-C is being studied as a model for understanding how mitochondrial functional status communicates with nuclear gene expression programs. This places it at the intersection of aging biology, metabolic disease research, and cellular stress response. Research using MOTS-C as a probe has contributed to better characterization of the mitochondrial peptidome more broadly.",
      },
      {
        heading: "Protocol and Purity Notes",
        body: "MOTS-C is a small, 16-residue peptide with a molecular weight of approximately 2174 Da. It is soluble in aqueous buffers and typically reconstituted in PBS or bacteriostatic water for in vitro use. Sequence fidelity is critical — single residue substitutions at key positions can abrogate AMPK activation. Researchers should verify identity by MS and confirm HPLC purity ≥98% before use. Stored lyophilized at −20°C, MOTS-C is stable for 24+ months under appropriate conditions.",
      },
      {
        body: "PeptoBuy supplies research-grade MOTS-C (10 mg lyophilized per vial) for qualified researchers and laboratories. Each batch is independently third-party tested with COA available on request. For in vitro research use only — not for human or animal consumption.",
      },
    ],
  },

];

export function getPost(slug: string): BlogPost | undefined {
  return posts.find((p) => p.slug === slug);
}
